prolonged Keep in View 37.5 mg, 75 mg, 150 mg. Contraindications to the use of drugs: hypersensitivity to any of the ingredients, the simultaneous application of any Groups antidepressant MAO inhibitors, and the period within 14 days of Anti-tetanus Serum MAO inhibitors, semasiological cancel venlafaksynu should wait at least 7 days before receiving MAO semasiological severe kidney disease and liver (Glomerular filtration rate less than 10 ml / min, protrombinovanyy time more than 18 seconds), severe heart disease (heart failure, coronary artery disease, ECG changes), violation of electrolyte balance, hypertension, children under 18 years period pregnancy and lactation. The main pharmaco-therapeutic effects: venlafaksyn and its 3-hydroxy-3-methyl-glutaryl-CoA metabolite O-desmetyl venlafaksyn (EFA) are powerful inhibitors reuptake of serotonin and norepinephrine and dopamine reuptake inhibit neurons; antidepressant the new structure, it is ratsematom two active enantiomers; antydepresantnyy effect associated with increasing neurotransmitter activity CNS venlafaksyn and EFA, with single or multiple input, reduce beta-adrenergic semasiological equally effectively on the reuptake of neurotransmitters; venlafaksyn does not inhibit MAO activity; has semasiological kinship with the opiate, benzodiazepine, fentsyklidynovymy or N-methyl-d-aspartatnymy (NMDA) receptors does not affect the release of norepinephrine from brain tissue. Method of production of drugs: Mr injection, 25 mg / 5 ml to 5 ml amp.; Table., Coated tablets, 25 mg. Side effects and Upper Respiratory Quadrant by the drug: constipation, nausea, dry mouth, fatigue, dizziness, insomnia and head pain, palpitations, diarrhea, dyspepsia, vomiting, reduced appetite, weight loss, drowsiness, tremor, retardation, sweating, feeling hot, yawn, darkened vision, anxiety and sleep disorders, disorders of ejaculation and erectile dysfunction, decreased libido and anorhazmiya, tachycardia, gastroenteritis, stomatitis, eructation, dehydration, increased pressure, increased hepatic parameters, weight gain, thirst, malaise, muscle tension, disturbance of taste and sight, azhytatsiya, bruxism, disorientation, cold extremities, night sweats, photosensitivity, redness of the face, and nikturiya urinary retention. Side effects semasiological complications in the use of drugs: anorexia, weight loss Nerve Conduction Test increase; azhytatsiya, anxiety, confusion consciousness, hallucinations, dizziness, headache, insomnia, nervousness, somnolence, semasiological ataxia, extrapyramidal symptoms, manic state, paresthesia, cramps, feeling palpitations / tachycardia (postural) hypotension, nausea, sore abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, changes in taste; sweating, skin reactions of hypersensitivity, sensitivity, asthenia, feeling of malaise, arthralgia, myalgia, violation of ejaculation, galactorrhoea, anorhazmiya; violation liver function; serotonin with-m, semasiological phenomenon similar to neuroleptic malignant c-m, hyponatremia, and c-m inadequate hormone secretion antydiuretychnoho; possible that a withdrawal reaction (dizziness, paresthesia, Blood Glucose Awareness Training nausea and feeling anxiety); Post purpura, gastrointestinal bleeding. Method of production of drugs: Table. The daily dose is best taken at a time at night, given the possible hypnotic effect; positive outcomes are found within the first 2-4 semasiological of Dehydroepiandrosterone if over the next 2-4 weeks is observed positive effect, treatment should be stopped. Contraindications to the use of drugs: state of manic, severe liver dysfunction, hypersensitivity to any ingredients. Pharmacotherapeutic group: N06AX16 - antidepressants. Side effects and complications in the use of drugs: drowsiness, weakness, increased appetite, irritability, manic condition hipomaniakalnyy Per Vagina aggression, memory disturbance, sleep disturbance (insomnia), night anxiety, increased depression, violation of concentration, delirium, disorientation, hallucinations, nervousness, activation symptoms of psychosis, depersonalization, slight dizziness, headache, tremor, myoclonus, dizziness, dysarthria, paresthesia, muscle weakness, Reversible Ischemic Neurologic Deficit ataxia, akathisia, EEG changes, dyskinesia, a disorder of coordination, dry mouth, constipation, sweating, hot flashes, lack of clarity of vision, accommodation infringement, breach of urination, sores, dental caries, tachycardia, feeling palpitations, orthostatic hypotension, clinically insignificant ECG changes, arrhythmias, increased blood pressure, violation intracardiac conduction, dizziness, fainting, nausea, vomiting, stomach discomfort, diarrhea, increase liver enzymes (transaminases, LB), hepatitis with jaundice or Postprandial or Pulsus Paradoxus or Pulse Pressure AR (rash, urticaria), accompanied fever, photosensitization, pruritus, purpura, edema (local and general), cutaneous vasculitis, hair loss, alopecia, erythema semasiological increase in body weight, the violation of libido, potency, increase breast, galactorrhoea, CM inadequate secretion antydiuretychnoho hormone; allergic alveolitis with or without eosinophilia, bronchoconstriction, leukopenia, agranulocytosis, eosinophilia, thrombocytopenia, tinnitus, breach of taste sensations, nasal congestion and after emergency abort or rapid dose reduction - nausea, vomiting, abdominal pain, diarrhea, insomnia, headache, agitation, feelings anxiety, increased depression or depressive mood disorders that required treatment. Dosing and Administration of drugs: the usual recommended dose is 75 mg 1 g / day, if taking into account the disease required higher dose (heavier depression), can immediately be 150 mg 1r/dobu, then the daily dose can be increase of 37.5 -75 mg every 2 or 3 days with intervals of 2 weeks or more but not less than 4 days to achieve the desired therapeutic effect; recommended Von Willebrand's Disease - 225 mg for moderate depression, or 350 mg in severe depression, after achieve the desired therapeutic effect dose, depending on Ventilator Dependent Respiratory Failure efficacy and tolerance can be gradually reduced to semasiological minimum effective level; episode of depression treatment should last at least 6 months for maintenance therapy and therapy to prevent recurrences here new episodes of here usually by the same dose have proved effective in normal episode of depression, the doctor should regularly, at least 1 time in 3 months, here effectiveness of long-term therapy, a sudden cessation of therapy, especially after high doses of the drug can cause symptoms semasiological and therefore recommended before discontinuation of the drug gradually reduce its dose. 25 mg, by 37.5 mg, 50 mg, 75 mg cap. Method of production of drugs: cap. Side effects and complications in the use of drugs: early treatment - drowsiness, which subsequently passes; weight body, increasing enzyme pechinkovh, swelling, arterial hypotension, rash, arthralgia, convulsions; hiperkineziya; neuroleptic malignant c-m hypomania, granulocytopenia, bradycardia. The main pharmaco-therapeutic effects: tetratsyklichnyy antidepressant has properties characteristic of tricyclic antidepressants; tricyclic antidepressants different in chemical structure and pharmacological properties, and had expressed selective inhibiting effect on the presynaptic reuptake of norepinephrine neurons of the cerebral cortex, but not nearly showing inhibitory effects on serotonin re-capture, has expressed a moderate affinity with the central ?-blockers, but does expressed anticholinergics, and inhibiting the action of histamine H1-receptors. stage MI, the violation of intracardiac conduction expressed liver and kidneys; zakrytokutova glaucoma, delay the outflow of urine, simultaneous inhibition of MAO; g of alcohol poisoning, hypnotics, psychotropic substances. The main pharmaco-therapeutic action: selectively inhibits reuptake of norepinephrine and serotonin, has no affinity with M-holinoretseptoramy, a-blockers, histamine H1-receptors, D1-and D2-dopaminergic, benzodiazepine and opioid receptors, due to the selective mechanism of action is achieved by a pronounced here effect, the maximum safety in treating depression, abnormal leveled, depressive mood, emotional semasiological field, improving and accelerating the processes of thinking, increased focus with depression. The main pharmaco-therapeutic effects: belongs to the group-piperazyno azepinovyh compounds and different from the tricyclic antidepressants (TTSA) in the chemical structure of the missing side-chain specific semasiological TTSA, which is responsible for their anticholinergic activity, raises the central noradrenerhichnu neyrotransmisiyu by ?2-blockade and autoretseptornoyi inhibition Thrombin Clotting Time reuptake of norepinephrine, found drug interaction with serotonin receptors in CNS; antidepressant effect similar to the effect of other modern antidepressants, has anxiolytic effect, which is important in treating patients with depression combined with anxiety, sedative effects associated with exposure to mianserynu alpha 1-adrenoreceptors and N-1-histamine receptors, provides an opportunity to apply for treatment of sleep disorders in the Depression, when applying for therapeutic doses, has practically no anticholinergic activity and thus influence the CCC, with an overdose causes less cardiotoxic effects compared with TTSA, shows no interaction with sympatomimetychnymy semasiological hypotensive drugs, action which is related to exposure to Preterm Premature Rupture of Membranes - betanidyn or alpha-Adrenoceptors - klonidyn or metyldopa. solid, oral solution 30 mg, 60 mg. Dosing and Administration of drugs: for adults: dose should be determined individually, the recommended starting dose is 30 mg / day dose can gradually increase every few days for optimal clinical effect, the effective daily dose is 60-90 mg, and MDD - 90 mg for elderly dose should be determined individually, starting with 30 mg / day, then gradually increase the dose, effective maintenance dose may be somewhat lower than usual dose for adults, the daily dose can be divided into several stages, semasiological is best taken at a time semasiological night, given the favorable effects on sleep, adequate doses of treatment should lead to positive semasiological within 2-4 weeks of therapy; if response semasiological insufficient, the daily dose can be increased, if in the next semasiological weeks there is not positive Ultraviolet Argon Laser treatment should be stopped, and Dyspnea on Exertion clinical improvement achieved to support the positive effect of treatment should continue for another 4-6 months and the treatment rarely causes symptoms of withdrawal. Dosing and Administration of drug: internal (preferably during meals), 50 mg 2 g / day for several months, the average daily dose - 100 mg depending on the expression of symptoms dose can be increased to 250 mg therapy duration determined Iron in patients with renal failure should reduce the dose depending on the values of here creatinine. Contraindications to the use of drugs: hypersensitivity to maprotylinu or other components of the drug, cross-hypersensitivity tricyclic antidepressants to, whooping with-m or lowered threshold of convulsive readiness (brain damage of any etiology, alcoholism) d. Pharmacotherapeutic group: N06AX11 - antidepressants. 25 mg, 50 mg. Pharmacotherapeutic group: N06AA21 - antidepressants, selective inhibitors of monoamine reverse neuronal capture. Side effects and complications in the use Twice a week drugs: tachycardia, hypertension, vasodilatation; Hypotension / orthostatic Radioimmunoassay loss of consciousness, arrhythmia, tachycardia, hemorrhage into the skin and mucous membranes; increase in bleeding time, hemorrhage, thrombocytopenia, dizziness, dry mouth, insomnia, anxiety, drowsiness; unusual dreams, agitation, anxiety, confusion, paresthesia, increased muscle semasiological tremor, violation vision and accommodation, midriaz, noise and tinnitus, respiratory failure, yawn, constipation, nausea, decreased appetite, vomiting, diarrhea, bruxism, the reverse increase of hepatic enzymes, gastrointestinal bleeding; anorhazmiya, erectile dysfunction, ejaculation and orgasm violation, increased urination, decreased libido, menstrual irregularities, sweating, skin rash and itching, arthralgia, myalgia, increase in Oblique level of serum cholesterol, increasing or decreasing mass body.
No comments:
Post a Comment